RE:Roche CD47 antibody start-up gives up-lays off all employeesThis development involving Arch Oncology places further pressure on Roche to do a deal with ONCY in an effort to bolster and expand the products and indications supporting Roche's existing product pipeline that is focused on their immune checkpoint inhibitor Tecentriq (atezolizumab).